Published in Front Pharmacol on December 07, 2016
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Identification of human brain tumour initiating cells. Nature (2004) 38.87
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
Mechanisms of angiogenesis. Nature (1997) 18.04
Convergence of Wnt, beta-catenin, and cadherin pathways. Science (2004) 13.13
A perivascular niche for brain tumor stem cells. Cancer Cell (2007) 11.55
Angiogenesis in brain tumours. Nat Rev Neurosci (2007) 6.82
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Stem cell concepts renew cancer research. Blood (2008) 6.74
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature (2010) 6.13
High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer (2004) 5.99
Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res (2008) 5.67
HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol (2006) 5.17
Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 4.78
Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett (2009) 4.45
Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene (2004) 4.29
Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol (1999) 4.25
Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell (2014) 4.04
SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell (2009) 3.89
Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell (2008) 3.87
Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell (2010) 3.82
TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell (2010) 3.69
Transport of molecules across tumor vasculature. Cancer Metastasis Rev (1987) 3.67
Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res (2005) 3.63
FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell (2011) 3.58
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (2009) 3.55
A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain (2010) 3.53
Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells (2007) 3.47
CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer (2008) 3.46
Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A (2011) 3.45
Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy. J Neurosurg (2013) 3.39
Recent insights into the role of Notch signaling in tumorigenesis. Blood (2005) 3.37
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell (2013) 3.32
Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res (2008) 3.22
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol (2015) 3.21
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell (2012) 3.19
The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development (2001) 3.14
Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell (2007) 3.14
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res (2009) 2.80
EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res (2009) 2.68
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell (2010) 2.68
Genetics of adult glioma. Cancer Genet (2012) 2.48
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev (2011) 2.48
STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells (2009) 2.46
Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg (2007) 2.43
c-Myc is required for maintenance of glioma cancer stem cells. PLoS One (2008) 2.41
A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics (2009) 2.21
NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J (2010) 2.01
Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene (2008) 1.95
Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. Genes Dev (2013) 1.88
BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci (2009) 1.85
Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene (2009) 1.85
Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis (2009) 1.70
Vasculogenesis, angiogenesis, and arteriogenesis: mechanisms of blood vessel formation and remodeling. J Cell Biochem (2007) 1.67
Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev (2011) 1.63
Toxicology of nanoparticles. Adv Drug Deliv Rev (2011) 1.60
Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One (2011) 1.57
CNS delivery via adsorptive transcytosis. AAPS J (2008) 1.46
Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol (2004) 1.42
Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res (2008) 1.41
The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J Pathol (2011) 1.36
An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep (2013) 1.35
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci U S A (2015) 1.31
A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci U S A (2011) 1.30
A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathol (2009) 1.28
Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Res (2010) 1.24
Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine (2010) 1.22
Notch signaling, brain development, and human disease. Pediatr Res (2005) 1.22
Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release (2005) 1.19
Mechanisms regulating glioma invasion. Cancer Lett (2015) 1.19
Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med (2013) 1.19
Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials (2011) 1.16
Coevolution in the tumor microenvironment. Nat Genet (2008) 1.16
Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor. Stem Cells (2012) 1.14
Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res (2006) 1.12
L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J (2011) 1.10
Neoplastic cells are a rare component in human glioblastoma microvasculature. Oncotarget (2012) 1.09
The blood-brain barrier: an engineering perspective. Front Neuroeng (2013) 1.09
Emerging insights into barriers to effective brain tumor therapeutics. Front Oncol (2014) 1.08
Safety assessment of nanomaterials: implications for nanomedicine. J Control Release (2012) 1.07
Targeting Aggressive Cancer Stem Cells in Glioblastoma. Front Oncol (2015) 1.05
Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stem-like cells. PLoS One (2013) 1.05
Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. Ann Surg Oncol (2011) 1.01
Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J Control Release (2006) 1.00
Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int J Pharm (2009) 0.96
Vasculogenic mimicry: a novel target for glioma therapy. Chin J Cancer (2013) 0.95
Altered expression of polycomb group genes in glioblastoma multiforme. PLoS One (2013) 0.95
CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia. Neuro Oncol (2013) 0.94
Molecular Trojan horses for blood-brain barrier drug delivery. Discov Med (2006) 0.94
Pericytes of the neurovascular unit: key functions and signaling pathways. Nat Neurosci (2016) 0.94
Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles. Int J Nanomedicine (2013) 0.92
Nanoparticles of 2-deoxy-D-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials (2013) 0.92
Molecular and cellular heterogeneity: the hallmark of glioblastoma. Neurosurg Focus (2014) 0.91
FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2. PLoS One (2015) 0.90
Real-time visualization of nanoparticles interacting with glioblastoma stem cells. Nano Lett (2015) 0.90
The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells. Mol Ther (2013) 0.89
Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting. Front Pharmacol (2016) 0.78
Drug Discovery via Human-Derived Stem Cell Organoids. Front Pharmacol (2016) 0.75
Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells. Front Pharmacol (2016) 0.75